Cargando…

Pharmacogenetics of Treatment Response in Psoriatic Arthritis

TNF-blocking agents, non-biological disease-modifying anti-rheumatic drugs (nbDMARDs) and non-steroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed treatments in psoriatic arthritis. A large proportion of patients do not respond to these medications, although unfortunately clinically us...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jani, Meghna, Barton, Anne, Ho, Pauline
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2015
Materias:	Psoriatic Arthritis (O Fitzgerald and P Helliwell, Section Editors)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4435910/ https://www.ncbi.nlm.nih.gov/pubmed/25980667 http://dx.doi.org/10.1007/s11926-015-0518-z

Ejemplares similares

Altered Bone Biology in Psoriatic Arthritis
por: Rahimi, Homaira, et al.
Publicado: (2012)

Investigation of association of the IL12B and IL23R genes with psoriatic arthritis
por: Filer, Charlotte, et al.
Publicado: (2008)

Baseline patient characteristics associated with response to biologic therapy in patients with psoriatic arthritis enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
por: Mease, Philip J, et al.
Publicado: (2018)

Psoriatic arthritis: an evolving matter
por: Wendling, Daniel
Publicado: (2015)

Distinguishing rheumatoid arthritis from psoriatic arthritis
por: Merola, Joseph F, et al.
Publicado: (2018)

Transition phase towards psoriatic arthritis: clinical and ultrasonographic characterisation of psoriatic arthralgia
por: Zabotti, Alen, et al.
Publicado: (2019)

Systematic literature review of domains assessed in psoriatic arthritis to inform the update of the psoriatic arthritis core domain set
por: Kalyoncu, Umut, et al.
Publicado: (2016)

Methotrexate treatment in early psoriatic arthritis in comparison to rheumatoid arthritis: an observational nationwide study
por: Lindström, Ulf, et al.
Publicado: (2023)

Burden of Psoriatic Arthritis According to Different Definitions of Disease Activity: Comparing Minimal Disease Activity and the Disease Activity Index for Psoriatic Arthritis
por: Wervers, Kim, et al.
Publicado: (2018)

Comparative Genetic Analysis of Psoriatic Arthritis and Psoriasis for the Discovery of Genetic Risk Factors and Risk Prediction Modeling
por: Soomro, Mehreen, et al.
Publicado: (2022)

Evolution of psoriatic arthritis study patient population characteristics in the era of biological treatments
por: Vandendorpe, Ann-Sophie, et al.
Publicado: (2019)

What makes psoriatic and rheumatoid arthritis so different?
por: Veale, Douglas James, et al.
Publicado: (2015)

Comparative effectiveness of biologics and targeted therapies for psoriatic arthritis
por: Zhang, Hanzhe, et al.
Publicado: (2021)

Real-world burden of comorbidities in US patients with psoriatic arthritis
por: Shah, Kamal, et al.
Publicado: (2017)

Association of synovial tissue polyfunctional T-cells with DAPSA in psoriatic arthritis
por: Wade, Sarah M, et al.
Publicado: (2019)

Measurement properties of the minimal disease activity criteria for psoriatic arthritis
por: Coates, Laura C, et al.
Publicado: (2019)

Ustekinumab Treatment and Improvement of Physical Function and Health‐Related Quality of Life in Patients With Psoriatic Arthritis
por: Rahman, Proton, et al.
Publicado: (2016)

Treatment‐to‐Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease Manifestations
por: Mease, Philip J., et al.
Publicado: (2020)

Construct validity and responsiveness of feasible composite disease activity measures for use in daily clinical practice in patients with psoriatic arthritis
por: Kasiem, Fazira R., et al.
Publicado: (2023)

Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2
por: Mease, Philip J, et al.
Publicado: (2021)

Role of clinical and biochemical inflammation in structural progression of patients with psoriatic arthritis
por: Borst, Carina, et al.
Publicado: (2021)

Axial spondyloarthritis and psoriatic arthritis: mostly overlapping or substantially different diseases?
por: Braun, Juergen, et al.
Publicado: (2023)

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial
por: Helliwell, Philip S, et al.
Publicado: (2022)

Differences in the serum metabolome and lipidome identify potential biomarkers for seronegative rheumatoid arthritis versus psoriatic arthritis
por: Souto-Carneiro, Margarida, et al.
Publicado: (2020)

Predictors of response to secukinumab in patients with psoriatic arthritis and axial manifestations: a post-hoc analysis of the MAXIMISE trial
por: Baraliakos, Xenofon, et al.
Publicado: (2022)

High burden of polypharmacy and comorbidity in persons with psoriatic arthritis: an analysis of claims data, stratified by age and sex
por: Albrecht, Katinka, et al.
Publicado: (2023)

Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a post hoc analysis of a phase III trial
por: McInnes, Iain B, et al.
Publicado: (2019)

Osteoporosis in psoriatic arthritis: a cross-sectional study of an outpatient clinic population
por: Gulati, Agnete Malm, et al.
Publicado: (2018)

Achilles enthesitis defined by ultrasound is not associated with clinical enthesitis in patients with psoriatic arthritis
por: Michelsen, Brigitte, et al.
Publicado: (2017)

Patient’s experience of psoriatic arthritis: a conceptual model based on qualitative interviews
por: Ogdie, Alexis, et al.
Publicado: (2020)

Disparities in healthcare in psoriatic arthritis: an analysis of 439 patients from 13 countries
por: Lucasson, Florian, et al.
Publicado: (2022)

Bone mineral density in patients with psoriatic arthritis: data from the Nord-Trøndelag Health Study 3
por: Gulati, Agnete Malm, et al.
Publicado: (2017)

Pharmacodynamic effects of filgotinib treatment driving clinical improvement in patients with active psoriatic arthritis enrolled in the EQUATOR trial
por: Chandran, Vinod, et al.
Publicado: (2023)

IL-23 skin and joint profiling in psoriatic arthritis: novel perspectives in understanding clinical responses to IL-23 inhibitors
por: Nerviani, Alessandra, et al.
Publicado: (2021)

Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib
por: de Vlam, Kurt, et al.
Publicado: (2021)

Multimodal imaging of the distal interphalangeal-joint synovio-entheseal complex in psoriatic arthritis (MIDAS): a cross-sectional study on the diagnostic accuracy of different imaging modalities comparing psoriatic arthritis to psoriasis and osteoarthritis
por: Guldberg-Møller, Jørgen, et al.
Publicado: (2022)

Evaluation of the Disease Activity index for PSoriatic Arthritis (DAPSA) with a quick quantitative C reactive protein assay (Q-DAPSA) in patients with psoriatic arthritis: a prospective multicentre cross-sectional study
por: Proft, Fabian, et al.
Publicado: (2022)

Patients with psoriatic arthritis who are not eligible for randomised controlled trials for TNF inhibitors have treatment response and drug survival similar to those who are eligible
por: Palsson, Olafur, et al.
Publicado: (2019)

Economic and Comorbidity Burden Among Moderate‐to‐Severe Psoriasis Patients with Comorbid Psoriatic Arthritis
por: Feldman, Steven R., et al.
Publicado: (2015)

Orthopaedic interventions in patients with psoriatic arthritis: a descriptive report from the SPAR cohort
por: Haque, Naba, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_aame62odplgrtvajolvvk79me6